EPHA3 and plasma cell myeloma: In addition to its role in T cell lymphomas, EphA3 also plays a role in multiple myeloma angiogenesis (150) suggesting that an effective anti-EphA3 therapy could be potentially utilized for treatment of both T and B cell malignancies.